News
Current report No. 16/2023 – Resolution of the Ordinary General Meeting of the Company on coverage of loss and payment of the dividend for the financial year 2022
Date prepared: July 22, 2023 Abbreviated name of the issuer: CELON PHARMA S.A. Subject: Resolution of the Ordinary General Meeting of the Company on coverage of loss and payment of the dividend for the financial year 2022 Legal basis Article 56 subs. 1 point 2 of the Act on Public Offering – current and periodicRead more »
Current report No. 15/2023 – Statement of the Central Securities Depository of Poland (KDPW) on assimilation of 21,500 C-series shares with the Company’s shares currently traded in the stock exchange
Date prepared: June 15, 2022 Abbreviated name of the issuer: CELON PHARMA S.A. Subject: Statement of the Central Securities Depository of Poland (KDPW) on assimilation of 21,500 C-series shares with the Company’s shares currently traded in the stock exchange Legal basis: Article 56 subs. 1 point 2 of the Act on Public Offering – currentRead more »
Current report 14/2023 – Admission and introduction of 21,500 ordinary C-series bearer shares of the Company to stock exchange trading
Date prepared: June 14, 2023 Abbreviated name of the issuer: CELON PHARMA S.A. Subject: Admission and introduction of 21,500 ordinary C-series bearer shares of the Company to stock exchange trading Legal basis Article 56 subs. 1 point 2 of the Act on Public Offering – current and periodic information Content of the report: The ManagementRead more »
Current report No. 13/2023 – Celon Pharma S.A.’s project on clinical development of the innovative CPL110 inhibitor in FGFR-dependant solid tumors will receive co-funding
Date prepared: June 13, 2023 Abbreviated name of the issuer: CELON PHARMA S.A. Subject: Celon Pharma S.A.’s project on clinical development of the innovative CPL110 inhibitor in FGFR-dependant solid tumors will receive co-funding Legal basis: Article 17 (1) of the Market Abuse Regulation (MAR) – inside information. Content of the report: The Management Board ofRead more »
Current report No. 12/2023 – Allocation of 21,500 C-series shares under a conditional share capital increase
Date prepared: June 13, 2023 Abbreviated name of the issuer: CELON PHARMA S.A. Subject: Allocation of 21,500 C-series shares under a conditional share capital increase Legal basis Article 56 subs. 1 point 2 of the Act on Public Offering – current and periodic information Content of the report: The Management Board of Celon Pharma S.A.Read more »
Current report No. 11/2023 – Notification on the acquisition of C-series shares of Celon Pharma S.A. by a person discharging managerial responsibilities
Date prepared: June 6, 2023 Abbreviated name of the issuer: CELON PHARMA S.A. Subject: Notification on the acquisition of C-series shares of Celon Pharma S.A. by a person discharging managerial responsibilities Legal basis: Article 19 section 3 of the Market Abuse Regulation (MAR) – information on transactions conducted by persons discharging managerial responsibilities. Content ofRead more »
Current report No. 10/2023 – Notice on the convening of the Ordinary General Meeting of Celon Pharma S.A. on June 22, 2023 with draft resolutions
Legal basis: Article 56 subs. 1 point 2 of the Act on Public Offering – current and periodic information The Management Board of Celon Pharma S.A. (“the Company”), acting pursuant to Article 395 § 1, Article 399 § 1, Article 402 (1) and Article 402 (2) of the Commercial Companies Code, hereby convenes the OrdinaryRead more »
Current report No. 9/2023 – The Management Board’s and the Supervisory Board’s recommendation on the coverage of loss for the year 2022 and payment of the dividend
Date prepared: May 17, 2023 Abbreviated name of the issuer: CELON PHARMA S.A. Subject: The Management Board’s and the Supervisory Board’s recommendation on the coverage of loss for the year 2022 and payment of the dividend Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) – inside information. Content of the report: Read more »
Current report No. 8/2023 – Notification about a transaction on subscription warrants of Celon Pharma S.A.
April 28, 2023, 02:40 PMLegal basis: Article 19 section 3 of the Market Abuse Regulation (MAR) – information on transactions conducted by persons discharging managerial responsibilities. Content of the report: The Management Board of Celon Pharma S.A. (the “Company”) hereby informs that on April 28, 2023, it received a notification from a person discharging managerialRead more »
Current report No. 7/2023 – Successful tender for the supply of Company’s products to the Persian Gulf countries
Date: April 26, 2023, time: 04:10 PM Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) – inside information. The Management Board of Celon Pharma S.A. (“Company”) hereby informs that on April 26, 2023, the Company was informed by Glenmark Pharmaceuticals Ltd. with its registered seat in India (“Glenmark”) about a positiveRead more »